Recon: Vertex, NHS reach deal for CF drugs; Canadian court dismisses drugmakers’ challenge to drug price rules

• After pandemic, US senators want review of drug supply chain (Reuters) (The Hill)
• Inovio claims positive results on Covid-19 vaccine but critical data are missing (STAT)
• Companies have raised prices on 245 drugs during pandemic, advocacy group says (The Hill)
• Gilead’s pricing for remdesivir raises questions about the drug’s long-term prospects (STAT)
• On a roll, Merck blazes through a new segment of the biomarker trail (Endpoints) (FDA)
• Pandemic unleashes a spike in overdose deaths (Politico)
• House Votes to Limit Health Costs as Drug Maker Adds Price Tag to Virus Treatment (NYTimes) (Politico)

• China Imports Stuck at India Ports Show Standoff Casualties (Bloomberg)
• Vertex and the UK government reach deal over cystic fibrosis medicines (STAT)
• Canada federal court dismisses drugmakers' plea challenging drug price rules (Reuters)
• The CEO of Novartis on Developing Drugs During a Pandemic (Wired)
• Pharma trade group scolds AstraZeneca for bad behavior over an advisory board (STAT)
• HIV treatment found to have no benefit for hospitalised COVID-19 patients in trial (Reuters)
• Coronavirus: Hydroxychloroquine trial to restart (BBC)
• Flu virus with 'pandemic potential' found in China (BBC) (NYTimes)

• Trial of T-cell coronavirus therapy approved in Scotland (Financial Times)
• South Korea Holds Onto Patient Data From Prior Coronavirus, Worrying Privacy Groups (NPR)
• Coronavirus (COVID-19) Update: Daily Roundup June 29, 2020 (FDA)
• HHS will renew public health emergency (Modern Healthcare)

• What to expect from ‘Modernizing the FDA’s Data Strategy’ meeting (STAT)
• A new FDA tool aims to inform cancer care, but experts say it has a glaring gap (STAT)
• The biotech scorecard for the third quarter: 14 stock-moving events to watch (STAT)
• The hedge fund manager behind a long-shot coronavirus pill (Financial Times)
• Opioid shortages open up a world of pain (Financial Times)
• With calls for American-made drugs on the rise, a Michigan CDMO is scaling up to meet demand (Fierce)
• Novavax hires new manufacturing chief to take COVID-19, flu vaccine hopefuls across the finish line (Fierce)
• US FDA, Industry Share Early Lessons From Complex Innovative Trial Designs Program (Pink Sheet)
• EU Remote Trials Project Gets Moving (Pink Sheet)
• Successful Elocta bid should widen access to the drug in the UK (PharmaTimes)
• Alnylam's RNAi therapy Givlaari shows lasting effect one year into treatment, new data show (Fierce)
• Takeda maps out a discovery alliance aimed at breaking through the safety and efficacy boundaries that limit the first-gen gene therapies (Endpoints) (Fierce)
• Elias Zerhouni discusses ‘amateur hour’ in DC, the destruction of infectious disease R&D and how we need to prep for the next time (Endpoints)
• Freeline nabs $120M, eyes IPO as its gene therapy comes into focus (Endpoints)
• Genmab, Seattle Genetics eye FDA filing for new cancer med after latest data drop (Fierce)
• Seattle Genetics, Genmab turn on TV for a highlight reel in cervical cancer — but a rival biotech promises a better show (Endpoints)
• Gilead-partnered Goldfinch Bio lands $100M as it pivots to clinical stage biotech (Endpoints)
• Zynerba flunks another PhII trial, all but ending Fragile X hopes (Endpoints)
• Menten AI Adds Quantum Computing to Develop New Drugs (WSJ)
• Rubius marks milestone in PhI/II as CFO departs; Owkin closes $70M Series A; The Carlyle Group bets on Indian CDMO (Endpoints)
• WHO urges countries to expand access to rapid molecular tests for the detection of TB and drug-resistant TBc (WHO)

• Q&A: New NESTcc chief on the real-world evidence group's 'pivot point' and COVID-19 (MedtechDive)
• What Next For Standards As CEN/CENELEC Reject MDR/IVDR Commission Request? (MedtechInsight)
• Brainlab picks up Level Ex, maker of video games for surgeons (Fierce)
• FDA nod to Boston Scientific cardiac monitor clears challenge to Abbott, Medtronic (MedtechDive)
• Masimo announces device designed to reduce opioid withdrawal symptoms (MobiHealthNews)
• Medtronic delivers real-world renal denervation data showing better blood pressure after 3 years (Fierce)

• How would a Biden White House handle drug prices? Depends on congressional races, analysts say (Fierce)
• New BPCIA Complaint: Genentech Seeks to Block Samsung Bioepis’s Proposed AVASTIN Biosimilar (Big Molecule Watch)
• AmerisourceBergen CEO Must Testify In Opioid Bellwether (Law360)
• Justices Told PTAB Appointments Are Not Unconstitutional (Law360)
• Bayer, GE Must Face Suit Over Woman's Chemical Sickness (Law360)
• Fortress Drops Ex-Theranos IP Suit To Let Test Co. Fight Virus (Law360)
• FDA Ducks Suit Challenging Stimulant Crackdown (Law360)